Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituxan IV for relapse prevention in neuromyelitis optica spectrum disorder – special use-results survey
jRCT2031220487Recruiting
- Sponsor
- Nippon Zenyaku Kogyo Co., Ltd.
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of rituximab in Neuromyelitis Optica Spectrum Disorder (NMOSD) and neuromyelitis optica (NMO), sponsored by Nippon Zenyaku Kogyo Co., Ltd. Primary endpoint: Incidence of adverse drug reactions and serious adverse events. Started Dec 2022; status: recruiting.
02
Drugs
rituximab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)neuromyelitis optica (NMO)
Beyond the preview
Go deeper on jRCT2031220487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220487.